Puma Biotechnology | PBYI - Процентные расходы





Процентные расходы Изменить Дата
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amgen USD 653M 32M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Daiichi Sankyo JPY 2.16B 1.33B 2025-12
Esperion Therapeutics USD 22.64M 585K 2025-12
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 255M 1000K 2025-12
Glaxosmithkline GBP 177.95M 6.05M 2025-09
Incyte USD 582K 10K 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
Moderna USD 12.14B 12.13B 2025-09
Novartis USD 304M 23M 2025-12
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Takeda JPY 123.63B 40.49B 2025-12
TG Therapeutics USD 6.53M 187K 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vanda Pharmaceuticals 601.14M 23.61M 2025-09
Vertex Pharmaceuticals USD 3.3M 0 2025-12